PCR (Phylasis Clinicas Research)

pcr.com.mx

Phylasis Clinicas Research S de RL de CV® (PCR) is a clinical research site in charge of supporting sponsors and CROs in the search for a competent and experienced research team. We know that the conduct of clinical studies plays an important role in the development of medications; and that the ethical conduct of the same, is the key to ensure high quality information that not only complies with the regulatory and research requirements; It also satisfies our moral responsibility to society. We work together with the pharmaceutical industry and medical specialists, facilitating interaction and ensuring confidentiality and responsibility.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

SARTORIUS STEDIM BIOTECH CLOSES ACQUISITION OF SLOVENIAN PURIFICATION SPECIALIST BIA SEPARATIONS

Sartorius | November 03, 2020

news image

Sartorius Stedim Biotech (SSB), a leading partner of the biopharma industry, successfully closed the acquisition of the Slovenian purification specialist BIA Separations. The transaction was completed on November 2, 2020, after receiving the required approvals. "BIA's portfolio is highly complementary to Sartorius Stedim Biotech. We are thus creating an excellent offering for the manufacturing of gene therapies and other advanced therapies, and are pleased to welcome 120 new employees,&...

Read More

CELL AND GENE THERAPY

X-THERMA CLOSES OVERSUBSCRIBED $13M SERIES A FINANCING LED BY LOREA AG

X-Therma Inc. | December 23, 2021

news image

X-Therma Inc., a biotechnology company developing breakthrough technology for regenerative medicine and organ preservation - has closed an oversubscribed $13M Series A funding round. The financing is led by LOREA AG, an entrepreneur-operated investment firm, with participation from Zen11 Holdings, Graphene Ventures, VU Venture Partners, 2b AHEAD Ventures, Methuselah Foundation, Catalytic Impact Foundation, along with notable return angel investors. X-Therma’s technology, a n...

Read More

MEDICAL

ABSCI OPENS DOOR TO NEW BIOTECHNOLOGY CAMPUS

Absci | October 23, 2021

news image

Absci Corporation the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the opening of its new campus located in Vancouver, Washington, a few miles east of the downtown location that housed the company for the last four years. “Absci has been an incredibly positive force in the Vancouver community since establishing its headquarters here in 2016 I have fol...

Read More

INDUSTRIAL IMPACT

VAXESS TECHNOLOGIES ANNOUNCES GRAND OPENING OF GMP MANUFACTURING FACILITY

Vaxess Technologies | October 27, 2021

news image

Vaxess Technologies, a biotechnology startup developing the MIMIXTM sustained-release intradermal microneedle patch, celebrated the grand opening of their 3,600 square feet pilot GMP (Good Manufacturing Practices) manufacturing facility on Monday. The facility, which is located in Woburn, MA at one of the Cummings Park properties, will feature a state-of-the-art cleanroom where manufacturing of vaccine patches for clinical trials will take place. Using the clinical-grade patches produced in the ...

Read More
news image

SARTORIUS STEDIM BIOTECH CLOSES ACQUISITION OF SLOVENIAN PURIFICATION SPECIALIST BIA SEPARATIONS

Sartorius | November 03, 2020

Sartorius Stedim Biotech (SSB), a leading partner of the biopharma industry, successfully closed the acquisition of the Slovenian purification specialist BIA Separations. The transaction was completed on November 2, 2020, after receiving the required approvals. "BIA's portfolio is highly complementary to Sartorius Stedim Biotech. We are thus creating an excellent offering for the manufacturing of gene therapies and other advanced therapies, and are pleased to welcome 120 new employees,&...

Read More
news image

CELL AND GENE THERAPY

X-THERMA CLOSES OVERSUBSCRIBED $13M SERIES A FINANCING LED BY LOREA AG

X-Therma Inc. | December 23, 2021

X-Therma Inc., a biotechnology company developing breakthrough technology for regenerative medicine and organ preservation - has closed an oversubscribed $13M Series A funding round. The financing is led by LOREA AG, an entrepreneur-operated investment firm, with participation from Zen11 Holdings, Graphene Ventures, VU Venture Partners, 2b AHEAD Ventures, Methuselah Foundation, Catalytic Impact Foundation, along with notable return angel investors. X-Therma’s technology, a n...

Read More
news image

MEDICAL

ABSCI OPENS DOOR TO NEW BIOTECHNOLOGY CAMPUS

Absci | October 23, 2021

Absci Corporation the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the opening of its new campus located in Vancouver, Washington, a few miles east of the downtown location that housed the company for the last four years. “Absci has been an incredibly positive force in the Vancouver community since establishing its headquarters here in 2016 I have fol...

Read More
news image

INDUSTRIAL IMPACT

VAXESS TECHNOLOGIES ANNOUNCES GRAND OPENING OF GMP MANUFACTURING FACILITY

Vaxess Technologies | October 27, 2021

Vaxess Technologies, a biotechnology startup developing the MIMIXTM sustained-release intradermal microneedle patch, celebrated the grand opening of their 3,600 square feet pilot GMP (Good Manufacturing Practices) manufacturing facility on Monday. The facility, which is located in Woburn, MA at one of the Cummings Park properties, will feature a state-of-the-art cleanroom where manufacturing of vaccine patches for clinical trials will take place. Using the clinical-grade patches produced in the ...

Read More